Verona Pharma plc Verona Pharma Plc: Pdmr Dealing

 
TIDMVRP 
 
   LONDON, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that, on August 8, 2019, Dr. David 
Ebsworth, Chairman of the Company, purchased a further 60,000 ordinary 
shares of 5 pence each in the Company (the "Ordinary Shares") at a price 
of 50 pence per Ordinary Share and a total purchase price of GBP30,000. 
This purchase brings the total purchases made by Dr. Ebsworth during 
2019 to approximately GBP80,000. 
 
   Following the acquisition, Dr. Ebsworth will have an interest in the 
Company of 295,387 Ordinary Shares, representing 0.28% of the Company's 
issued share capital. 
 
   The notification set out below is provided in accordance with the 
requirements of the EU Market Abuse Regulation. 
 
 
 
 
1   Details of the person discharging managerial responsibilities/person 
     closely associated 
    ---------------------------------------------------------------------- 
a)  Name                                       David Ebsworth 
    -----------------------------------------  --------------------------- 
2   Reason for the notification 
    ---------------------------------------------------------------------- 
a)  Position/status                            Chairman 
    -----------------------------------------  --------------------------- 
b)  Initial notification/Amendment             Initial notification 
    -----------------------------------------  --------------------------- 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
    ---------------------------------------------------------------------- 
a)  Name                                       Verona Pharma plc 
    -----------------------------------------  --------------------------- 
b)  LEI                                        213800EVI6O6J3TIAL06 
    -----------------------------------------  --------------------------- 
 
 
 
 
 
 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
    -------------------------------------------------------------------------- 
a)  Description of the        Ordinary Shares of 5 pence each 
    financial instrument, 
    type of instrument 
    Identification code       GB00BYW2KH80 
    ------------------------  ------------------------------------------------ 
b)  Nature of the             David Ebsworth purchased 60,000 Ordinary Shares 
    transaction 
 
c)  Price(s) and volume(s)            Price(s)                Volume(s) 
                              ------------------------  ---------------------- 
                              50 pence per Ordinary     60,000 Ordinary Shares 
                              Share 
                              ------------------------  ---------------------- 
 
d)  Aggregated information    N/A 
    - Aggregated volume 
    - Price 
    ------------------------  ------------------------  ---------------------- 
e)  Date of the transaction   8 August 2019 
    ------------------------  ------------------------------------------------ 
f)  Place of the transaction  London Stock Exchange, AIM 
    ------------------------  ------------------------------------------------ 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer       info@veronapharma.com 
 Victoria Stewart, Director of Communications 
 
N+1 Singer                                         Tel: +44 (0)20 7496 3000 
 (Nominated Adviser and UK Broker) 
Aubrey Powell / Jen Boorer / Iqra Amin (Corporate 
 Finance) 
Mia Gardner (Corporate Broking)
(END) Dow Jones Newswires
August 09, 2019 04:35 ET (08:35 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024